Every year, adverse drug events claim an estimated 100,000 to 128,000 lives in the United States alone.¹ They also drive more than 700,000 emergency department visits, 100,000 hospitalizations,² and $5 billion in annual treatment costs³ — a significant share of it preventable. For decades, clinicians, researchers, and patient advocates around the world have been building the science and the clinical evidence to change that.

Mira Precision Health is rolling out a new version of a DPYD pharmacogenomic test designed to help cancer patients avoid severe toxicities from widely used chemotherapies, initially targeting large hospital systems in the US.

David Kerr is an internationally recognized leader in colorectal cancer research, clinical trials, and cancer systems innovation. He is Professor of Cancer Medicine at the University of Oxford and has played a central role in shaping modern gastrointestinal oncology.

Mira Precision Health today announced the official U.S. launch of ToxNav^® Advantage^™, a clinically validated pharmacogenomic assay designed to identify cancer patients at increased risk of severe or potentially life-threatening toxicities from fluoropyrimidine-based chemotherapies, including 5-fluorouracil (5-FU) and capecitabine (XELODA^®).